• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Lupin gets tentative approval from US FDA for empagliflozin tablets

expresspharmaAugust 05, 2020

Tag: lupin , empagliflozin tablets , Diabetes

Lupin has received tentative approval for its empagliflozin tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (US FDA) to market a generic version of Jardiance Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Empagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin Tablets, 10 mg and 25 mg had an annual sales of approximately $4,368 million in the US (IQVIA MAT Mar 2020).


Previous:Kokate Committee releases list of 471 rational FDCs

Next:Manslaughter charges on Sanofi over epilepsy drug Depakine

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Lupin gets tentative approval from US FDA for empagliflozin tablets | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

N-BOC-3-hydroxypiperidine (Lilaliptin for diabetes)

N-BOC-3-hydroxypiperidine (Lilaliptin for diabetes)
Lupeol-98%-Lupinus Albus Extracts

Lupeol-98%-Lupinus Albus Extracts
6-chloro-3-methyluracil (agliptin and trogliptin for diabetes)

6-chloro-3-methyluracil (agliptin and trogliptin for diabetes)
Refilled Diabetes insulin pen in disposable use with 3ml Cartridge in plastic materials

Refilled Diabetes insulin pen in disposable use with 3ml Cartridge in plastic materials
Portable Diabetes Insulin Pen in Attractive Design

Portable Diabetes Insulin Pen in Attractive Design
Acarbose EP used for Diabetes treatment made in China

Acarbose EP used for Diabetes treatment made in China
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Miglitol 99%min Pharmaceutical Diabetes drug made in china

Miglitol 99%min Pharmaceutical Diabetes drug made in china
Refillable Insulin Pen, Insulin Injection Devices For Diabetes patients self-administration

Refillable Insulin Pen, Insulin Injection Devices For Diabetes patients self-administration
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service